Browsing Tag
Beijing
41 posts
VNET Group (NASDAQ: VNET) rallies as CATL stake and 517 MW order book reset AI thesis
CATL is taking 38% of VNET for nearly $1 billion. Wholesale just passed retail. The question is whether China's AI capex cycle reaches the bottom line.
May 27, 2026
BAI Capital raises $600m in first close of new Asia growth fund
Asia growth capital is getting more selective. BAI Capital’s US$600M first close shows where disciplined investors may still see upside.
May 22, 2026
Trump leaves Taiwan arms sale undecided after Xi warning in Beijing talks
Taiwan needs deterrence. China wants restraint. Donald Trump’s arms sale pause turns one weapons package into an Indo Pacific credibility test.
May 16, 2026
Xi warns Trump on Taiwan as US and China push trade deals in Beijing
Trump and Xi are chasing trade stability. Taiwan remains the fault line that could still pull United States China ties into crisis.
May 15, 2026
Lavrov in Beijing as China and Russia coordinate on Iran war and Trump threatens 50% tariff over weapons shipment
China's Wang Yi condemned the US Iran port blockade as Russia's Lavrov visited Beijing, with a weapons shipment intelligence report deepening US-China friction.
April 14, 2026
Is Cathay General Bancorp (Nasdaq: CATY) a quiet bank stock to watch before earnings?
Cathay General Bancorp (Nasdaq: CATY) heads into April 22 earnings near its 52-week high. Read what matters next for this regional bank stock.
April 10, 2026
Biocytogen just stacked two cancer bets in three days. Is its platform strategy starting to compound?
Biocytogen’s NEOK002 IND clearance and Moonlight Bio deal highlight a platform-led oncology strategy. Read what it means for growth and sentiment.
March 27, 2026
GSK’s Shingrix wins China approval for adults 18+ — Can this vaccine expansion reignite its global growth story?
Find out how GSK’s Shingrix approval in China for adults aged 18+ could reshape its vaccine business and investor confidence. #GSK #Shingrix
October 15, 2025
Avistone Biotechnology presents positive ASCO 2025 results for dual inhibitor therapy in EGFR-mutated NSCLC
Avistone reveals 50% ORR and 9.9-month PFS for its Vebreltinib–Andamertinib combo in MET-amplified NSCLC at ASCO 2025. Find out what this means for lung cancer care.
June 1, 2025
Xi Jinping unveils new measures to stabilise China’s economy amid trade war escalations
China launches stimulus to counter economic slowdown; Politburo signals targeted U.S. tariff cuts as part of stabilisation drive.
April 26, 2025